265 related articles for article (PubMed ID: 29799326)
1. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
Graham J; Earnshaw S; Burslem K; Lim J
J Manag Care Spec Pharm; 2018 Jun; 24(6):544-553. PubMed ID: 29799327
[TBL] [Abstract][Full Text] [Related]
3. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
4. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
5. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
6. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
[TBL] [Abstract][Full Text] [Related]
7. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
Ramsey SD; Clarke L; Kamath TV; Lubeck D
J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
[TBL] [Abstract][Full Text] [Related]
9. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
Sorensen S; Ellis L; Wu Y; Hutchins V; Linnehan JE; Senbetta M
J Manag Care Pharm; 2013; 19(9):799-808. PubMed ID: 24156649
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
Appukkuttan S; Farej R; Miles L; Purser M; Wen L
J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
[No Abstract] [Full Text] [Related]
11. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
12. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Schultz NM; O'Day K; Sugarman R; Ramaswamy K
J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
14. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
Park K; Cho EK; Bello M; Ahn MJ; Thongprasert S; Song EK; Soldatenkova V; Depenbrock H; Puri T; Orlando M
Cancer Res Treat; 2017 Oct; 49(4):937-946. PubMed ID: 28111429
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
[TBL] [Abstract][Full Text] [Related]
18. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Carlson JJ; Wong WB; Veenstra DL; Reyes C
J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
[TBL] [Abstract][Full Text] [Related]
20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]